Abstract
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have